THE GALIEN FOUNDATION

PRODUCT: **XOSPATA®**

COMPANY: Astellas Pharma Inc.

THERAPEUTIC AREA & INDICATION:
Tyrosine kinase inhibitor for adults with relapsed or refractory acute myeloid leukemia (AML) with the tyrosine kinase-3 gene mutation

ABOUT THE PRODUCT

Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd., and Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib. XOSPATA® is approved in the U.S., Japan, Europe, Canada, Korea, Brazil and Australia for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation, and is currently undergoing regulatory review in China.

Gilteritinib has demonstrated inhibitory activity against FLT3-ITD, a type of FLT3mut+ that is seen in approximately one-third of patients with AML, as well as FLT3-TKD mutation.

THE GALIEN FOUNDATION

PRODUCT: **XPOVIO®**

COMPANY: Karyopharm Therapeutics Inc.

THERAPEUTIC AREA & INDICATION:
Treatment of relapsed/refractory (RR) multiple myeloma and RR diffuse large B-cell lymphoma

ABOUT THE PRODUCT

XPOVIO® (selinexor) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins. XPOVIO received accelerated FDA approval in July 2019 in combination with dexamethasone for the treatment of adult patients with penta-refractory multiple myeloma. Karyopharm's sNDA requesting an expansion of its current indication to include the treatment for patients with multiple myeloma after at least one prior line of therapy has also been accepted for filing by the FDA. In June 2020, XPOVIO received accelerated FDA approval for its second indication in adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least 2 lines of systemic therapy.

THE GALIEN FOUNDATION

PRODUCT: **Adakveo® (crizanlizumab-tmca)**

COMPANY: Novartis Pharmaceuticals Corporation

THERAPEUTIC AREA & INDICATION:
Treatment to lower frequency of recurrent vaso-occlusive crises associated with severe vascular system pain for conditions like sickle cell anemia

ABOUT THE PRODUCT

Adakveo is the first and only FDA-approved, monthly targeted medicine that has been shown to reduce the annual rate of sickle cell pain crises to 1.63 vs 2.98 (equivalent to -45%) and the annual rate of days hospitalized to 4 vs 6.87 (-42%). The most common side effects (incidence ≥10%) include nausea, back pain, joint pain, and fever.

THE GALIEN FOUNDATION

PRODUCT: **Gamifant®**

COMPANY: Sobi

THERAPEUTIC AREA & INDICATION:

First treatment for infants/adults with primary haemophagocytic lymphohistiocytosis (HLH), an ultra-rare immune disorder that leads to severe inflammation, infections, bleeding, organ failures and early death

ABOUT THE PRODUCT

Gamifant® (emapalumab-lzsg) is the first and only medicine approved by the FDA for primary haemophagocytic lymphohistiocytosis (HLH), an ultra-rare syndrome of hyperinflammation that can rapidly become fatal unless diagnosed and treated. Gamifant is indicated for paediatric and adult primary HLH patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy.

Visit www.gamifant.com for more information, including full Prescribing Information.